If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  TOURETTE SYMPOSIUM: Cholinergic Agent Offers Relief From Tics In Tourette Syndrome NEW YORK, NY -- June 7, 1999 -- Significant reduction in Tourette syndrome symptoms was noted in a study of nine affected adults after they received a medication not usually prescribed for this neurologic disorder, according to data presented by Emory University researchers at this week's third International Scientific Symposium on Tourette Syndrome. Low doses of tacrine hydrochloride reduced involuntary movements and vocalisations (motor and vocal tics), according to quantifiable measurements taken by investigators. In contrast, high doses did not work or could aggravate the symptoms. "Additional analyses revealed dose-related improvement in comorbid symptoms, such as self-reported attentional difficulties, hyperactivity, impulsivity and obsessive thinking," reports principal investigator Jorge Juncos, M.D., associate professor of neurology at the Emory University School of Medicine, and colleagues, in the abstract. Tacrine is a cholinergic agent that promotes acetylcholine transmission in the brain. It is currently approved for the management of selected memory disorders but not for Tourette syndrome. In contrast to Tacrine, drugs that block acetylcholine transmission can aggravate tic and need to be used cautiously in Tourette syndrome, Dr. Juncos said. Current treatments for Tourette syndrome work on other neurotransmitters. For instance, dopamine blockers such as haloperidol can alleviate tics at the expense of a number of side effects. Prozac (fluoxetine) and Zoloft (sertraline), which act upon the serotonin system, lessen obsessive-compulsive symptoms associated with Tourette but may aggravate tics in some cases. Other useful drug classes include blood pressure medications like Catapres (clonidine), botulinum toxin injections occasionally used to relieve facial tics and stimulants such as Ritalin (methylphenidate) used to relieve ADHD symptoms. "Low doses of tacrine seemed to address not only the tic symptoms but other symptoms like inattention, impulsivity and obsession which tend to be more disabling than the tics themselves," Dr. Juncos said. "Nonetheless, tacrine is not an ideal drug since it is short acting and needs to be taken four times a day. It can also cause liver damage, thus requiring periodic monitoring of the liver profile. "The findings with tacrine, however, provide hope that perhaps other agents in this category currently under investigation may prove safer and more effective." Tourette syndrome is a neurologic disorder usually diagnosed in children under age 21. Average age of patients in the current study was 24. The characteristic motor and vocal tics associated with the disorder are mild in the majority of patients and often diminish or stabilise with age. Although the public often associates coprolalia with Tourette syndrome, this is in fact a relatively rare but socially disabling symptom. Coprolalia is considered a complex vocal tic and consists of involuntary swearing in public. However, many children with Tourette also exhibit symptoms of ADHD such as short attention span, poor concentration, impulsivity and hyperactivity, Dr. Juncos explained.
|
